BlackRock Investment Management’s Acceleron Pharma XLRN Stock Holding History

BlackRock Investment Management’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$3.8M	Buy	148,729 +14,065	+10%	+$446K	﹤0.01%	1780
2016 Q3	$4.87M	Buy	134,664 +206	+0.2%	+$6.82K	0.01%	1502
2016 Q2	$4.57M	Buy	134,458 +16,696	+14%	+$543K	0.01%	1498
2016 Q1	$3.11M	Buy	117,762 +13,183	+13%	+$383K	﹤0.01%	1699
2015 Q4	$5.1M	Buy	104,579 +255	+0.2%	+$9.18K	0.01%	1374
2015 Q3	$2.6M	Buy	104,324 +161	+0.2%	+$4.84K	﹤0.01%	1874
2015 Q2	$3.3M	Buy	104,163 +30,577	+42%	+$987K	﹤0.01%	1829
2015 Q1	$2.8M	Buy	73,586 +2,483	+3%	+$98.7K	﹤0.01%	1794
2014 Q4	$2.77M	Buy	71,103 +14,089	+25%	+$491K	﹤0.01%	1790
2014 Q3	$1.72M	Buy	57,014 +192	+0.3%	+$5.41K	﹤0.01%	2107
2014 Q2	$1.93M	Buy	56,822 +36,416	+178%	+$1.22M	﹤0.01%	2096
2014 Q1	$704K	Buy	20,406 +3,537	+21%	+$160K	﹤0.01%	2761
2013 Q4	$668K	Buy	+16,869	New	+$407K	﹤0.01%	2791

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 39.77% 1-Year Est. Return

BlackRock Investment Management's XLRN Position: Q4 2016 in Review

BlackRock Investment Management increased its Acceleron Pharma (XLRN) stake by 10% in Q4 2016, buying an estimated $446K and bringing the position to 148,729 shares worth $3.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1780.

BlackRock Investment Management first reported a position in XLRN in Q4 2013 and has held it in 13 quarters since. The position peaked at $5.1M in Q4 2015. 146 funds tracked by Wall St. Rank hold XLRN as of Q4 2016.

BlackRock Investment Management held 148,729 shares of Acceleron Pharma worth $3.8M as of Q4 2016.
BlackRock Investment Management bought 14,065 Acceleron Pharma shares in Q4 2016, an estimated $446K.
Acceleron Pharma made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #1780 holding.
BlackRock Investment Management first reported a position in Acceleron Pharma in Q4 2013 and has held it in 13 quarters since.
BlackRock Investment Management's Acceleron Pharma position peaked at $5.1M in Q4 2015.
146 funds tracked by Wall St. Rank held Acceleron Pharma as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.